TipRanks tools are all you need to make data-driven investment decisions. Conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts, with ease.
The Moleculin Biotech stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia. The company's preclinical small molecule portfolios focus on the modulation of hard-to-target tumor cell signaling mechanisms and the metabolism of tumors. Moleculin Biotech was founded by Walter V. Klemp, Donald H. Picker and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.
What was Moleculin Biotech’s price range in the past 12 months?
Moleculin Biotech lowest stock price was $2.70 and its highest was $8.78 in the past 12 months.
What is Moleculin Biotech’s market cap?
Moleculin Biotech’s market cap is $88.80M.
What is Moleculin Biotech’s price target?
The average price target for Moleculin Biotech is $23.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $29.00 ,the lowest forecast is $18.00. The average price target represents 655.63% Increase from the current price of $3.11.
What do analysts say about Moleculin Biotech?
Moleculin Biotech’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
When is Moleculin Biotech’s upcoming earnings report date?
Moleculin Biotech’s upcoming earnings report date is Nov 16, 2021 which is in 2 months.
How were Moleculin Biotech’s earnings last quarter?
Moleculin Biotech released its earnings results on Aug 12, 2021. The company reported -$0.149 earnings per share for the quarter, beating the consensus estimate of -$0.187 by $0.038.
Is Moleculin Biotech overvalued?
According to Wall Street analysts Moleculin Biotech’s price is currently Undervalued.
Does Moleculin Biotech pay dividends?
Moleculin Biotech does not currently pay dividends.
What is Moleculin Biotech’s EPS estimate?
Moleculin Biotech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Moleculin Biotech have?
Moleculin Biotech has 28,550,000 shares outstanding.
What happened to Moleculin Biotech’s price movement after its last earnings report?
Moleculin Biotech reported an EPS of -$0.149 in its last earnings report, beating expectations of -$0.187. Following the earnings report the stock price went down -3.257%.
Which hedge fund is a major shareholder of Moleculin Biotech?
Currently, no hedge funds are holding shares in MBRX